Cellivery Therapeutics, Inc.
KOE: 268600.KQ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Daewoong Jo
- Employees
- 22
- Headquarters
- Seoul, South Korea
- IPO year
- 2018
- Market cap
- ₩248.4B
- Website
- http://www.cellivery.com
Loading 268600…
Loading profile data…Frequently asked questions about 268600
What does Cellivery Therapeutics, Inc. (268600.KQ) do?
Cellivery Therapeutics, Inc. researches and develops therapeutic drugs for life-threatening lethal diseases, such as cancer, inflammation, metabolic, and neurodegenerative diseases. It develops small molecule, antibody, and vaccine drugs based on its Therapeutic molecule Systemic Delivery Technology. The company was founded in 2014 and is based...
Where does 268600.KQ trade?
Cellivery Therapeutics, Inc. (268600.KQ) trades on the KOSDAQ.
What sector is 268600.KQ in?
Cellivery Therapeutics, Inc. (268600.KQ) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Cellivery Therapeutics, Inc.?
Daewoong Jo is the chief executive officer of Cellivery Therapeutics, Inc. (268600.KQ).
Where is Cellivery Therapeutics, Inc. headquartered?
Cellivery Therapeutics, Inc. is headquartered in South Korea.
Does 268600.KQ pay a dividend?
Cellivery Therapeutics, Inc. (268600.KQ) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 268600.KQ go public?
Cellivery Therapeutics, Inc. (268600.KQ) completed its initial public offering in 2018.